摘要
瞄准：由在造影剂注射以后评估损害和胰腺的实质的对比举起特征在焦点的胰腺的群众和像团的损害中调查 mangafodipir trisodium (MnDPDP ) 的角色。方法：有胰腺的集体或像团的损害的 37 个病人的一个总数被 unenhanced 和提高 MnDPDP 的磁性的回声成像(MRI ) 检验。结果：在 MnDPDP 和同类的对比改进的注入在正常的胰实质被观察以后， MRI 是获得的 20-40 min。在有衰退的胰的病人，在提高 MnDPDP 的 MRI 上的胰腺的实质没有改进。在有 41 胰腺的群众和像团的损害的 37 个病人，对比改进在 MnDPDP 上在 5 损害被观察提高的 MRI。这 5 损害中的三个是焦点的胰腺炎和其它 2 是腺癌。没有对比改进在 32 个病人在 36 胰腺的群众和像团的损害中被决定。结论：特别在没有实质萎缩的情况中， MnDPDP 提高对比的 MRI 能区分焦点的胰腺的损害边缘。胰腺的实质的功能的信息能从肿瘤被获得。MnDPDP 在肝由变形损害的察觉便于胰腺的肿瘤的阶段。另外，减少了在有胰腺炎的病人的 MnDPDP 的 heteregenous 举起可能在鉴别诊断是有用的。
AIM： To investigate the role of mangafodipir trisodium （MnDPDP） in focal pancreatic masses and mass-like lesions by evaluating contrast uptake features of the lesions and pancreatic parenchyma after contrast medium injection.
METHODS： A total of 37 patients with pancreatic mass or mass-like lesions were examined by unenhanced and MnDPDP-enhanced magnetic resonance imaging （MRI）. RESULTS： MRI was obtained 20-40 min after infusion of MnDPDP and homogeneous contrast enhancement was observed in normal pancreas parenchyma. In patients with atrophic pancreas there was no enhancement in pancreatic parenchyma on MnDPDP-enhanced MRI. In 37 patients with 41 pancreatic masses and mass-like lesions, contrast enhancement was observed at 5 lesions on MnDPDP enhanced MRI. Three of these 5 lesions were focal pancreatitis and the other 2 were adenocarcinoma. No contrast enhancement was determined in 36 pancreatic masses and mass-like lesions in 32 patients.
CONCLUSION： MnDPDP contrast-enhanced MRI, especially in cases with no parenchyma atrophy, can distinguish focal pancreatic lesion margins. Information about the function of pancreatic parenchyma can be obtained out of tumor. MnDPDP facilitates staging of pancreatic tumors by detection of metastatic lesions in the liver. In addition, diminished heteregenous uptake of MnDPDP in patients with pancreatitis may be helpful in differential diagnosis.
